Advancing immunosuppression in liver transplantation: A narrative review.
(2024) Hepatobiliary & Pancreatic Diseases International — Vol. 23, n° 5, p. 441-448 (2024)
Files
2024_Iesari_Hepatobiliary_Pancreat_Dis_Int.pdf
Restricted Access - Adobe PDF
- 547.69 KB
Details
- Authors
- Abstract
- Immunosuppression is essential to ensure recipient and graft survivals after liver transplantation (LT). However, our understanding and management of the immune system remain suboptimal. Current immunosuppressive therapy cannot selectively inhibit the graft-specific immune response and entails a significant risk of serious side effects, i.e., among others, de novo cancers, infections, cardiovascular events, renal failure, metabolic syndrome, and late graft fibrosis, with progressive loss of graft function. Pharmacological research, aimed to develop alternative immunosuppressive agents in LT, is behind other solid-organ transplantation subspecialties, and, therefore, the development of new compounds and strategies should get priority in LT. The research trajectories cover mechanisms to induce T-cell exhaustion, to inhibit co-stimulation, to mitigate non-antigen-specific inflammatory response, and, lastly, to minimize the development and action of donor-specific antibodies. Moreover, while cellular modulation techniques are complex, active research is underway to foster the action of T-regulatory cells, to induce tolerogenic dendritic cells, and to promote the function of B-regulatory cells. We herein discuss current lines of research in clinical immunosuppression, particularly focusing on possible applications in the LT setting.
- Affiliations
Citations
Iesari, S., Nava, F. L., Zais, I. E., Coubeau, L., Ferraresso, M., Favi, E., & Lerut, J. (2024). Advancing immunosuppression in liver transplantation: A narrative review. Hepatobiliary & Pancreatic Diseases International, 23(5), 441-448. https://doi.org/10.1016/j.hbpd.2024.03.001 (Original work published 2024)